I am a
Home I AM A Search Login

Papers of the Week

2022 Apr 02

J Neurovirol

Post-COVID-19 olfactory dysfunction: carbamazepine as a treatment option in a series of cases.


Vasconcelos C C F, Hammerle M B, Sales D S, Rueda Lopes F C, Pinheiro P G, Gouvea E G, Alves M C D F, Pereira T V, Schmidt S L, Alvarenga R M P, Pires K L
J Neurovirol. 2022 Apr 02.
PMID: 35366736.


Olfactory dysfunction is reported frequently in patients with coronavirus disease 2019. However, an effective treatment for this dysfunction is unknown. The present study evaluated carbamazepine as a treatment option for olfactory dysfunction based on its use in cases of neuralgia, especially of the V cranial nerve. The study included 10 patients with coronavirus disease with olfactory complaints who were part of a cohort of 172 coronavirus disease patients monitored for late neurological manifestations. Carbamazepine was administered for 11 weeks. The adverse effects reported were drowsiness (9/10) and dizziness (2/10); 9 of the 10 patients reported improved olfactory function after carbamazepine treatment. While the role of carbamazepine in the control of post-coronavirus disease olfactory dysfunction could not be confirmed in this study, the satisfactory response observed in most patients in this series suggests that further studies are warranted.